The use of prophylactic or therapeutic antiepileptic medication is common in patients undergoing bone marrow transplantation (BMT). Here, we report about two siblings who experienced severe graft failure attributed to druginduced hypersensitivity syndrome (DIHS) after treatment with phenytoin.
Patient 1 is a 9-year-old girl of African descent who underwent allogeneic unmanipulated BMT (cell dose of 3.9 Â 10 8 nucleated cells per kg body weight) from a human leukocyte antigen-matched unrelated donor for homozygous sickle cell anemia. The indication for BMT was based on the history of a life-threatening hepatic sequestration crisis, non-responsiveness to hydroxyurea treatment, and intractable hemolysis caused by alloimmunization against the hemagglutination inhibition antigen, which made transfusion therapy impossible. As the preparative regimen contained busulfan in addition to fludarabine and antithymocyte globuline, the patient received phenytoin for prophylaxis of seizures. We planned to continue this prophylaxis after BMT because of the specific propensity of patients suffering from sickle cell anemia for seizures. Despite adequate serum phenytoin levels, the patient experienced seizures with typical magnetic resonance imaging findings under graft-versus-host-disease (GVHD) prophylaxis with ciclosporin, which was changed to tacrolimus. Hematologic engraftment was complete with 495% donor-derived hematopoiesis after transplantation. Four months after BMT, the patient developed hepatitis with elevated liver enzymes (Table 1) and an increase in cholestasis parameters. Bilirubin remained within the normal range (10 mmol/l). A test for detection of viral pathogens was negative. Because of suspected drug toxicity, tacrolimus and phenytoin doses were reduced and fluconazole prophylaxis was discontinued. One week later, phenytoin was discontinued. Three weeks later, the patient was admitted to the hospital with fever, skin rash, itching and pancytopenia. Clinical and laboratory findings are summarized in Table 1 . Chimerism at this point remained at 94% donor hematopoiesis. A bone marrow aspirate showed trilineage aplasia; a skin biopsy revealed interface dermatitis with apoptosis not typical of GVHD. Despite broad-spectrum antimicrobial therapy the patient's condition deteriorated rapidly requiring bilevel positive airway pressure-assisted ventilation and catecholamines for circulatory support. Within hours of administration of 2 mg/kg prednisone (suspecting DIHS), the patient's condition improved substantially. However, despite immunosuppressive treatment and administration of granulocyte-macrophage colony stimulating factor (GM-CSF), her bone marrow graft failed to recover. Therefore, a decision for a second BMT using a different unrelated donor was made. The patient had an uncomplicated second transplant course. Twelve months after the second BMT she is alive and well, although suffering from limited chronic skin GVHD.
Patient 2 is the 6-year-old brother of patient 1. He received an allogeneic bone marrow transplant (3.8 Â 10 8 nucleated cells per kg body weight) from the same donor for homozygous sickle cell disease after recurrent cerebral infarctions. Following an uncomplicated transplant course with full hematologic engraftment (96% donor chimerism), the patient continued on phenytoin seizure prophylaxis. Four months after transplantation, he showed signs of moderate hepatitis (Table 1) with no viral pathogen detected. Three weeks later, the patient was admitted to our hospital with fever, cervical lymphadenopathy, periorbital edema and an exfoliative rash (Figure 1 ). Peripheral blood counts showed agranulocytosis and Coombs-positive mild hemolytic anemia but normal platelet counts. Bone marrow cytology revealed a maturation arrest at the promyelocyte stage. No pathogen was identified; cytomegalovirus (CMV) and Epstein-Barr virus (EBV)-PCR were negative. Despite broad-spectrum antimicrobial treatment, the fever persisted. Antineutrophil antibodies were detected in the patient's serum. Because of suspected DIHS, phenytoin was discontinued. The patient's condition improved rapidly after administration of dexamethasone pulse therapy. Following treatment with GM-CSF, neutrophils recovered to normal values within 2 months. The patient is alive and well without immunosuppressive medication 1.5 years after BMT.
Both patients were presented at the same time to our hospital. Although the etiology could not be completely verified, several clinical and laboratory findings pointed towards the diagnosis of DIHS: fever, skin rash, lymphadenopathy, periorbital edema, hepatitis, pulmonary failure and blood count abnormalities.
1,2 Occasionally, kidney involvement ranging from proteinuria or nephritis to renal failure is observed in patients with DIHS (for review see Gogtay et al. 3 and Pichler 4 ). Antiepileptic drugs (including phenytoin, phenobarbital, carbamazepin, valproic acid and lamotrigin) are known to cause DIHS in a small proportion of patients (estimated incidence 1:1000 to 1:10 000). In addition, sulfa-containing drugs (sulfasalazine and sulfametoxazole) and some other drugs (for example, allopurinol) may trigger DIHS. Crossreactivity between antiepileptic drugs has frequently been reported. Onset can be as early as 1 week up to 3 months after start of drug administration. Importantly, DIHS may occur after the drug has been withdrawn. Differential diagnosis may be extremely difficult in patients after BMT; graft rejection is the most important of them, but seems unlikely in our patients as donor-derived hematopoietic chimerism remained 480% in patient 1 and 494% in patient 2. Skin rash presenting either as maculopapular erythroderma or ichthyotic desquamation may resemble acute or chronic GVHD, respectively. Liver GVHD is an important differential diagnosis for elevated liver enzymes, but in our patients no increase in bilirubin was noticed. Viral infections, such as EBV or CMV, may be suspected if fever, lymphadenopathy and rash are present. There are some case reports about the coincidence of human herpesvirus 6 infection and DIHS. It is unclear, however, whether there is a pathogenic role for viral infections in DIHS or whether infections are secondary to immune dysfunction. 5, 6 Interestingly, there seems to be a genetic disposition as siblings of affected patients have up to 25% risk of developing a similar reaction after exposure to the same drug. 7, 8 Significance of different ethnic backgrounds is uncertain, as a slightly higher incidence in persons of African descent may be attributed to more frequent indication for use of antiepileptics in this population. 1 The exact mechanism of toxicity is still unclear, but it may be attributed to genetic variants of metabolic enzymes involved in the detoxification of aromatic antiepileptic drugs, for example, members of the epoxide hydrolase enzymatic pathway. 9 Metabolites may be directly toxic or act as haptens leading to autoimmune or hypersensitivity reactions. Beeler et al. 10 detected high frequencies of drugspecific T cells after severe systemic DIHS. Alternatively, specific antibodies, such as antineutrophil antibodies have been detected in some patients with drug hypersensitivity, 3 indicating that this syndrome may be more complex than a single entity involving T-cell as well as B-cell immunity. So far, there is no specific laboratory or clinical test to precisely diagnose DIHS. If DIHS is assumed, the suspected drug should be discontinued and potentially cross-reactive drugs should be avoided. The treatment of DIHS is mainly based on supportive-care measures. In severe cases, steroids can be administered (for example, prednisone 1-2 mg/kg daily), which will also improve other immune-mediated conditions. If antiepileptic prophylaxis or treatment is necessary, clonazepam is considered to be a safe treatment option, as DIHS has not been reported in the context of this drug. Prognostic scores for outcome after DIHS are currently not available.
In summary, drug-induced hypersensitivity is a potential rare reason for graft failure after BMT. However, in patients presenting with fever, skin rash, blood cell dyscrasia and systemic organ involvement, DIHS should be considered. Diagnostic tests such as drug-specific antineutrophil Table 1 Clinical and laboratory parameters of the two patients with DIHS at presentation 
